Law360, New York (May 11, 2012, 12:11 PM ET) -- Drug company Depomed Inc. lodged a patent infringement suit Wednesday in New Jersey in an effort to block plans by Indian drugmaker Cadila Healthcare Ltd. and its U.S. subsidiary to market a generic version of epilepsy medication Gralise.
California-based Depomed brought suit after Cadila and Zydus Pharmaceuticals (USA) Inc. sought federal approval of an abbreviated new drug application to make and sell a generic version of Gralise before Depomed’s six patents had expired.
“Zydus has declared its intent to manufacture, use, offer to sell or sell...
Depomed Sues Cadila, Zydus Over Generic Gralise
To view the full article, take a free trial now.
